If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
583.00    -5.00 (-0.85%)
Bid:
581.00
Ask:
583.00
Spread: 2.00 (0.344%)
Market Cap: £507.94m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Market Update

7 Apr 2020 07:00

RNS Number : 9729I
Victrex PLC
07 April 2020
 

 

 

 

 

 

 

 

7 April 2020

 

Victrex plc - market update

 

 'Solid H1 trading, strong financial position, proactive actions on COVID-19'

Victrex plc, an innovative world leader in high performance polymer solutions, today announces a market update covering trading, its financial position and proactive actions on COVID-19.

H1 trading

Trading for the first half year has been solid and in line with expectations:

· Solid volume growth, including a strong finish in March

· Good growth in Automotive and Medical, with a stable performance in Aerospace, Electronics and Value-Added Resellers, offset by weakness in Energy

· H1 2020 inventory c£100m, with high sales stock across US, Europe and Asia; appropriate raw material inventory in the UK and supply chain functioning well

Strong financial position

Victrex is part of multiple supply chains, many of which are supporting critical applications, for example in Medical. The Group retains a strong balance sheet to maintain customer, supplier and investor confidence and to ensure it has sufficient resources to invest and underpin future growth:

· The Group has facilities of £40m, comprising a committed and undrawn RCF of £20m and a £20m accordion, to October 2024

· Net cash position on 31 March of £42.2m, after payment of FY19 final dividend in February

Whilst Victrex benefits from a net cash position, we are acutely aware of the near-term uncertainty at a macro and end-market level, and have prudently implemented appropriate measures to reduce cost and conserve cash, whilst maintaining strong service levels for customers:

· Capital expenditure for UK debottlenecking programme now deferred to FY 2021

· Other capital programmes limited to essential only expenditure

· Operating cost items being limited to prioritise and support customer related activity

· China capacity investment continuing on plan

Other cash conservation measures will remain under review, which could include future shareholder dividends.

 

 

 

Proactive actions on COVID-19

The safety and well-being of Victrex employees continues to be our highest priority. We established a COVID-19 committee at the start of 2020, with a proactive approach and a range of contingency plans already implemented:

· People: we continue to follow governmental or state guidance wherever we operate

· Customers: we continue to serve customers from home offices, with all of our global employees' homeworking, wherever roles are not production related

· Essential industry: the UK government defines Chemicals as an essential industry with essential workers, with Victrex also having a long-standing history in supporting many critical and "life-sustaining" applications, particularly in Medical

o UK operations: reflecting government guidance and requirements in many "life-sustaining" applications, we are continuing to produce aligned to demand, supplemented by high buffer inventory if required

o US operations: we continue to operate on an ongoing modified basis, defined as being a 'life-sustaining' organisation in several states

· Ventilators: in addition to companies we already serve, we are supplying materials for Ventilators or related equipment to a number of global companies

Outlook

Although trading has remained in line with expectations year-to-date and the third quarter has shown early signs of a solid start, including some normal demand returning across parts of Asia, the macro-economic and end-market outlook over the coming months is very uncertain, particularly for Europe and the US.

It is therefore too early to provide guidance for the remainder of the current financial year. We will continue to produce for essential business, monitoring appropriate guidelines and assessing other cash conservation measures as required.

Victrex will report its interim results on 11 May 2020.

 

About Victrex:

 

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of automotive, aerospace, energy (including manufacturing & engineering), electronics and medical. Every day, millions of people use products and applications which contain our materials - from smartphones, aeroplanes and cars to oil and gas operations and medical devices. With over 40 years' experience, we develop world leading solutions in PEEK and PAEK based polymers, semi-finished and finished parts which shape future performance for our customers and our markets, and drive value for our shareholders. Find out more at www.victrexplc.com or follow us on LinkedIn and Twitter @victrexir

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Corporate Communications

+44 (0) 7809 595831

 

Jakob Sigurdsson, Chief Executive

+44 (0) 1253 897700

 

Richard Armitage, Group Finance Director

+44 (0) 1253 897700

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFLFLDSVIRIII
Date   Source Headline
18th Oct 20194:01 pmRNSHolding(s) in Company
18th Oct 20192:20 pmRNSDirector/PDMR Shareholding
16th Oct 201911:04 amRNSAdditional Listing
11th Oct 20194:18 pmRNSHolding(s) in Company
8th Oct 20193:09 pmRNSHolding(s) in Company
7th Oct 20194:06 pmRNSHolding(s) in Company
3rd Oct 20194:18 pmRNSHolding(s) in Company
30th Sep 201911:53 amRNSTotal Voting Rights
18th Sep 20199:19 amRNSDirector/PDMR Shareholding
30th Aug 20199:00 amRNSTotal Voting Rights
19th Aug 201911:44 amRNSDirector/PDMR Shareholding
14th Aug 201910:39 amRNSHolding(s) in Company
31st Jul 20199:01 amRNSTotal Voting Rights
25th Jul 20197:00 amRNSInterim Management Statement
17th Jul 201910:38 amRNSDirector/PDMR Shareholding
28th Jun 20199:00 amRNSTotal Voting Rights
24th Jun 20197:00 amRNSDirectorate Change
18th Jun 201910:42 amRNSDirector/PDMR Shareholding
3rd Jun 20191:55 pmRNSBlock listing Interim Review
31st May 20193:12 pmRNSDirector/PDMR Shareholding
31st May 20199:00 amRNSTotal Voting Rights
20th May 201910:09 amRNSDirector/PDMR Shareholding
17th May 201910:50 amRNSDirector/PDMR Shareholding
15th May 20198:49 amRNSDirector/PDMR Shareholding
13th May 20197:00 amRNSHalf-year Report
30th Apr 201910:00 amRNSTotal Voting Rights
17th Apr 201912:03 pmRNSDirector/PDMR Shareholding
29th Mar 201912:07 pmRNSTotal Voting Rights
19th Mar 201910:55 amRNSDirector/PDMR Shareholding
28th Feb 20199:33 amRNSTotal Voting Rights
19th Feb 201910:42 amRNSDirector/PDMR Shareholding
18th Feb 20194:23 pmRNSDirector/PDMR Shareholding
11th Feb 20194:34 pmRNSHolding(s) in Company
8th Feb 20199:44 amRNSHolding(s) in Company
6th Feb 20192:28 pmRNSResult of AGM
6th Feb 20191:55 pmRNSDirector/PDMR Shareholding
6th Feb 20197:00 amRNSAGM and Q1 Interim Management Statement
4th Feb 201912:18 pmRNSDirector/PDMR Shareholding
31st Jan 20199:29 amRNSTotal Voting Rights
28th Jan 20194:28 pmRNSHolding(s) in Company
17th Jan 201911:21 amRNSDirector/PDMR Shareholding
11th Jan 20193:44 pmRNSHolding(s) in Company
3rd Jan 20191:00 pmRNSAnnual Financial Report
31st Dec 20189:00 amRNSTotal Voting Rights
18th Dec 20183:19 pmRNSDirector/PDMR Shareholding
18th Dec 201810:30 amRNSDirector/PDMR Shareholding
17th Dec 201811:40 amRNSDirector/PDMR Shareholding
11th Dec 20189:50 amRNSDirector/PDMR Shareholding
11th Dec 20189:48 amRNSDirector/PDMR Shareholding
5th Dec 20181:47 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.